Germline genetic markers for urinary bladder cancer risk, prognosis and treatment response

Future Oncology

Volumn 6, Issue 9, 2010, Pages 1433-1460

  Grotenhuis, Anne J ^a   Vermeulen, Sita H ^a   Kiemeney, Lambertus A ^a,b  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b Integraal Kankercentrum Oost   (Netherlands)

Author keywords

bladder cancer; candidate gene study; genetic susceptibility; genome wide association study; pharmacogenomics; prognosis; therapy response

Indexed keywords

ARYLAMINE ACETYLTRANSFERASE; BCG VACCINE; CISPLATIN; DOXORUBICIN; GEMCITABINE; GLUTATHIONE TRANSFERASE M1; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; METHOTREXATE; VINBLASTINE;

AMINO ACID SUBSTITUTION; BLADDER CANCER; CANCER INVASION; CANCER RISK; CANCER STAGING; CANCER SURVIVAL; CANCER SUSCEPTIBILITY; CYSTECTOMY; EPITHELIAL MESENCHYMAL TRANSITION; GENE LOCUS; GENETIC ASSOCIATION; GENETIC MARKER; GENETIC SUSCEPTIBILITY; GERM LINE; HUMAN; METASTASIS; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; SINGLE NUCLEOTIDE POLYMORPHISM; SURVIVAL RATE; TREATMENT OUTCOME; TREATMENT RESPONSE; URINARY DIVERSION;

DRUG RESISTANCE, NEOPLASM; GENETIC PREDISPOSITION TO DISEASE; GENOME-WIDE ASSOCIATION STUDY; HUMANS; POLYMORPHISM, SINGLE NUCLEOTIDE; PROGNOSIS; RISK FACTORS; TUMOR MARKERS, BIOLOGICAL; URINARY BLADDER NEOPLASMS;

EID: 77957962663     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/fon.10.109     Document Type: Review

References (100)

1. Ploeg M, Aben KK, Kiemeney LA: The present and future burden of urinary bladder cancer in the world. World J. Urol. 27(3), 289-293 (2009).
2. Ferlay J, Bray F, Pisani P, Parkin DM: GLOBOCAN 2002: cancer incidence, mortality and prevalence worldwide. IARC CancerBase No.5.version 2.0., International Agency for Research on Cancer Press, France (2004).
3. Ploeg M, Aben KK, Hulsbergen-van de Kaa CA, Schoenberg MP, Witjes JA, Kiemeney LA: Clinical epidemiology of nonurothelial bladder cancer: analysis of The Netherlands Cancer Registry. J. Urol. 183(3), 915-920 (2010).
4. Wu X, Ros MM, Gu J, Kiemeney L: Epidemiology and genetic susceptibility to bladder cancer. BJU Int. 102(9 Pt B), 1207-1215 (2008).
5. Fletcher O, Easton D, Anderson K, Gilham C, Jay M, Peto J: Lifetime risks of common cancers among retinoblastoma survivors. J. Natl Cancer Inst. 96(5), 357-363 (2004).
6. Kleinerman RA, Tucker MA, Tarone RE et al.: Risk of new cancers after radiotherapy in long-term survivors of retinoblastoma: an extended follow-up. J. Clin. Oncol. 23(10), 2272-2279 (2005).
7. Marees T, Moll AC, Imhof SM, de Boer MR, Ringens PJ, van Leeuwen FE: Risk of second malignancies in survivors of retinoblastoma: more than 40 years of follow-up. J. Natl Cancer Inst. 100(24), 1771-1779 (2008).
8. Quezada E, Gripp KW: Costello syndrome and related disorders. Curr. Opin. Pediatr. 19(6), 636-644 (2007).
9. Aben KK, Witjes JA, Schoenberg MP, Hulsbergen-van de KC, Verbeek AL, Kiemeney LA: Familial aggregation of urothelial cell carcinoma. Int. J. Cancer 98(2), 274-278 (2002)
10. Murta-Nascimento C, Silverman DT, Kogevinas M et al.: Risk of bladder cancer associated with family history of cancer: do low-penetrance polymorphisms account for the increase in risk? Cancer Epidemiol. Biomarkers Prev. 16(8), 1595-1600 (2007).
11. Aben KK, Baglietto L, Baffoe-Bonnie A et al.: Segregation analysis of urothelial cell carcinoma. Eur. J. Cancer 42(10), 1428-1433 (2006).
12. Kiemeney LA: Hereditary bladder cancer. Scand. J. Urol. Nephrol. Suppl. 218, 110-115 (2008).
13. Sylvester RJ: Natural history, recurrence, and progression in superficial bladder cancer. ScientificWorldJournal 6, 2617-2625 (2006).
14. Babjuk M, Oosterlinck W, Sylvester R, Kaasinen E, Bohle A, Palou-Redorta J: EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder. Eur. Urol. 54(2), 303-314 (2008).
15. Sylvester RJ, van der Meijden AP, Oosterlinck W et al.: Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur. Urol. 49(3), 466-1465 (2006).
16. Stenzl A, Cowan NC, De Santis M et al.: The updated EAU guidelines on muscle-invasive and metastatic bladder cancer. Eur. Urol. 55(4), 815-825 (2009).
17. Kiemeney LA, Thorlacius S, Sulem P et al.: Sequence variant on 8q24 confers susceptibility to urinary bladder cancer. Nat. Genet. 40(11), 1307-1312 (2008).
18. Kiemeney LA, Sulem P, Besenbacher S et al.: A sequence variant at 4p16.3 confers susceptibility to urinary bladder cancer. Nat. Genet. 42(5), 415-419 (2010).
19. Wu X, Ye Y, Kiemeney LA et al.: Genetic variation in the prostate stem cell antigen gene PSCA confers susceptibility to urinary bladder cancer. Nat. Genet. 41(9), 991-995 (2009).
20. Brandau S , Suttmann H: Thirty years of BCG immunotherapy for non-muscle invasive bladder cancer: a success story with room for improvement. Biomed. Pharmacother. 61(6), 299-305 (2007).
21. Saint F, Salomon L, Quintela R et al.: Do prognostic parameters of remission versus relapse after Bacillus Calmette-Guerin (BCG) immunotherapy exist? Analysis of a quarter century of literature. Eur. Urol. 43(4), 351-360 (2003).
22. Ott OJ, Rodel C, Weiss C et al.: Radiochemotherapy for bladder cancer. Clin. Oncol. (R. Coll. Radiol.) 21(7), 557-565 (2009).
23. Bellmunt J, Albiol S, Suarez C, Albanell J: Optimizing therapeutic strategies in advanced bladder cancer: update on chemotherapy and the role of targeted agents. Crit. Rev. Oncol. Hematol. 69(3), 211-222 (2009).
24. Bellmunt J, Choueiri TK, Fougeray R et al.: Prognostic factors in patients with advanced transitional cell carcinoma of the urothelial tract experiencing treatment failure with platinum-containing regimens. J. Clin. Oncol. 28(11), 1850-1855 (2010).
25. Horikawa Y, Gu J, Wu X: Genetic susceptibility to bladder cancer with an emphasis on gene-gene and gene- environmental interactions. Curr. Opin. Urol. 18(5), 493-498 (2008).
26. Kiemeney LA, Grotenhuis AJ, Vermeulen SH, Wu X: Genome-wide association studies in bladder cancer: first results and potential relevance. Curr. Opin. Urol. 19(5), 540-546 (2009).
27. Kiltie AE: Common predisposition alleles for moderately common cancers: bladder cancer. Curr. Opin. Genet. Dev. 20(3), 218-224 (2010).
28. Malats N: Genetic epidemiology of bladder cancer: scaling up in the identification of low-penetrance genetic markers of bladder cancer risk and progression. Scand. J. Urol. Nephrol. Suppl. 218, 131-140 (2008).
29. Wu X, Lin X, Dinney CP, Gu J, Grossman HB: Genetic polymorphism in bladder cancer. Front. Biosci. 12, 192-213 (2007).
30. Wu X, Hildebrandt MA, Chang DW: Genome-wide association studies of bladder cancer risk: a field synopsis of progress and potential applications. Cancer Metastasis Rev. 28(3-4), 269-280 (2009).
31. Garcia-Closas M, Malats N, Silverman D et al.: NAT2 slow acetylation, GSTM1 null genotype, and risk of bladder cancer: results from the Spanish Bladder Cancer Study and meta-analyses. Lancet 366(9486), 649-659 (2005).
32. Garcia-Closas M, Malats N, Real FX et al.: Large-scale evaluation of candidate genes identifies associations between VEGF polymorphisms and bladder cancer risk. PLoS. Genet. 3(2), E29 (2007).
33. Stern MC, Lin J, Figueroa JD et al.: Polymorphisms in DNA repair genes, smoking, and bladder cancer risk: findings from the international consortium of bladder cancer. Cancer Res. 69(17), 6857-6864 (2009).
34. The International HapMap Consortium: A haplotype map of the human genome. Nature 437(7063), 1299-1320 (2005).
35. Frazer KA, Ballinger DG, Cox DR et al.: A second generation human haplotype map of over 3.1 million SNPs. Nature 449(7164), 851-861 (2007).
36. Lander ES, Linton LM, Birren B et al.: Initial sequencing and analysis of the human genome. Nature 409(6822), 860-921 (2001).
37. Kruglyak L: The road to genome-wide association studies. Nat. Rev. Genet. 9(4), 314-318 (2008).
38. Chung CC, Magalhaes WC, Gonzalez-Bosquet J, Chanock SJ: Genome-wide association studies in cancer - current and future directions. Carcinogenesis 31(1), 111-120 (2010).
39. Ioannidis JP, Thomas G, Daly MJ: Validating, augmenting and refining genome-wide association signals. Nat. Rev. Genet. 10(5), 318-329 (2009).
40. Nilsson JA, Cleveland JL: Myc pathways provoking cell suicide and cancer. Oncogene 22(56), 9007-9021 (2003).
41. Knowles MA: Bladder cancer subtypes defined by genomic alterations. Scand. J. Urol. Nephrol. Suppl. 218, 116-130 (2008).
42. Ahmadiyeh N, Pomerantz MM, Grisanzio C et al.: 8q24 prostate, breast, and colon cancer risk loci show tissue-specific long-range interaction with MYC. Proc. Natl Acad. Sci. USA 107(21), 9742-9746 (2010).
43. Wang M, Wang M, Zhang W et al.: Common genetic variants on 8q24 contribute to susceptibility to bladder cancer in a Chinese population. Carcinogenesis 30(6), 991-996 (2009).
44. Saeki N, Gu J, Yoshida T, Wu X: Prostate stem cell antigen: a Jekyll and Hyde molecule? Clin. Cancer Res. 16(14), 3533-3538 (2010).
45. Urist MJ, Di Como CJ, Lu ML et al.: Loss of p63 expression is associated with tumor progression in bladder cancer. Am. J. Pathol. 161(4), 1199-1206 (2002).
46. Koga F, Kawakami S, Fujii Y et al.: Impaired p63 expression associates with poor prognosis and uroplakin III expression in invasive urothelial carcinoma of the bladder. Clin. Cancer Res. 9(15), 5501-5507 (2003).
47. Rafnar T, Sulem P, Stacey SN et al.: Sequence variants at the TERT-CLPTM1L locus associate with many cancer types. Nat. Genet. 41(2), 221-227 (2009).
48. Hernandez S, Lopez-Knowles E, Lloreta J et al.: Prospective study of FGFR3 mutations as a prognostic factor in nonmuscle invasive urothelial bladder carcinomas. J. Clin. Oncol. 24(22), 3664-3671 (2006).
49. Park JH, Wacholder S, Gail MH et al.: Estimation of effect size distribution from genome-wide association studies and implications for future discoveries. Nat. Genet. 42(7), 570-575 (2010).
50. Wu X, Lin J, Grossman HB et al.: Projecting individualized probabilities of developing bladder cancer in white individuals. J. Clin. Oncol. 25(31), 4974-4981 (2007).
51. Via M, Gignoux C, Burchard EG: The 1000 Genomes Project: new opportunities for research and social challenges. Genome Med. 2(1), 3 (2010).
52. Hirschhorn JN: Genome-wide association studies - illuminating biologic pathways. N. Engl. J. Med. 360(17), 1699-1701 (2009).
53. Andrew AS, Gui J, Sanderson AC et al.: Bladder cancer SNP panel predicts susceptibility and survival. Hum. Genet. 125(5-6), 527-539 (2009).
54. Castillejo A, Rothman N, Murta-Nascimento C et al.: TGFB1 and TGFBR1 polymorphic variants in relationship to bladder cancer risk and prognosis. Int. J. Cancer 124(3), 608-613 (2009).
55. Wendt MK, Allington TM, Schiemann WP: Mechanisms of the epithelial-mesenchymal transition by TGF-b. Future Oncol. 5(8), 1145-1168 (2009).
56. Marsh HP, Haldar NA, Bunce M et al.: Polymorphisms in tumour necrosis factor (TNF) are associated with risk of bladder cancer and grade of tumour at presentation. Br. J. Cancer 89(6), 1096-1101 (2003).
57. Sakano S, Kumar R, Larsson P et al.: A single-nucleotide polymorphism in the XPG gene, and tumour stage, grade, and clinical course in patients with nonmuscle-invasive neoplasms of the urinary bladder. BJU Int. 97(4), 847-851 (2006).
58. Gu J, Grossman HB, Dinney CP, Wu X: The pharmacogenetic impact of inflammatory genes on bladder cancer recurrence. Pharmacogenomics 6(6), 575-584 (2005).
59. Leibovici D, Grossman HB, Dinney CP et al.: Polymorphisms in inflammation genes and bladder cancer: from initiation to recurrence, progression, and survival. J. Clin. Oncol. 23(24), 5746-5756 (2005).
60. Ahirwar D, Kesarwani P, Manchanda PK, Mandhani A, Mittal RD: Anti- and proinflammatory cytokine gene polymorphism and genetic predisposition: association with smoking, tumor stage and grade, and bacillus Calmette-Guerin immunotherapy in bladder cancer. Cancer Genet. Cytogenet. 184(1), 1-8 (2008).
61. Gu J, Zhao H, Dinney CP et al.: Nucleotide excision repair gene polymorphisms and recurrence after treatment for superficial bladder cancer. Clin. Cancer Res. 11(4), 1408-1415 (2005).
62. Sakano S, Wada T, Matsumoto H et al.: Single nucleotide polymorphisms in DNA repair genes might be prognostic factors in muscle-invasive bladder cancer patients treated with chemoradiotherapy. Br. J. Cancer 95(5), 561-570 (2006).
63. Sanyal S, de Verdier PJ, Steineck G et al.: Polymorphisms in XPD, XPC and the risk of death in patients with urinary bladder neoplasms. Acta Oncol. 46(1), 31-41 (2007).
64. Sanyal S, Ryk C, de Verdier PJ et al.: Polymorphisms in NQO1 and the clinical course of urinary bladder neoplasms. Scand. J. Urol. Nephrol. 41(3), 182-190 (2007). (Pubitemid 46676357)
65. Shinohara A, Sakano S, Hinoda Y et al.: Association of TP53 and MDM2 polymorphisms with survival in bladder cancer patients treated with chemoradiotherapy. Cancer Sci. 100(12), 2376-2382 (2009).
66. Tsuchiya N, Inoue T, Narita S et al.: Drug related genetic polymorphisms affecting adverse reactions to methotrexate, vinblastine, doxorubicin and cisplatin in patients with urothelial cancer. J. Urol. 180(6), 2389-2395 (2008).
67. Yokomizo A, Yamamoto K, Kinukawa N, Tsunoda T, Koga H, Naito S: Association analysis of glutathione-S-transferase P1 (GSTP1) polymorphism with urothelial cancer susceptibility and myelosuppression after M-VAC chemotherapy. Int. J. Urol. 14(6), 500-504 (2007).
68. Rabik CA, Dolan ME: Molecular mechanisms of resistance and toxicity associated with platinating agents. Cancer Treat. Rev. 33(1), 9-23 (2007).
69. Kang S, Ju W, Kim JW et al.: Association between excision repair cross-complementation group 1 polymorphism and clinical outcome of platinum-based chemotherapy in patients with epithelial ovarian cancer. Exp. Mol. Med. 38(3), 320-324 (2006).
70. Pare L, Marcuello E, Altes A et al.: Pharmacogenetic prediction of clinical outcome in advanced colorectal cancer patients receiving oxaliplatin/5-fluorouracil as first-line chemotherapy. Br. J. Cancer 99(7), 1050-1055 (2008).
71. Suk R, Gurubhagavatula S, Park S et al.: Polymorphisms in ERCC1 and grade 3 or 4 toxicity in non-small cell lung cancer patients. Clin. Cancer Res. 11(4), 1534-1538 (2005). (Pubitemid 40315237)
72. Sun X, Li F, Sun N et al.: Polymorphisms in XRCC1 and XPG and response to platinum-based chemotherapy in advanced non-small cell lung cancer patients. Lung Cancer 65(2), 230-236 (2009).
73. Wang M, Wang M, Yuan L et al.: A novel XPF-357A>C polymorphism predicts risk and recurrence of bladder cancer. Oncogene 29(13), 1920-1928 (2010).
74. Rha SY, Jeung HC, Choi YH et al.: An association between RRM1 haplotype and gemcitabine-induced neutropenia in breast cancer patients. Oncologist 12(6), 622-630 (2007).
75. Soo RA, Wang LZ, Ng SS et al.: Distribution of gemcitabine pathway genotypes in ethnic Asians and their association with outcome in non-small cell lung cancer patients. Lung Cancer 63(1), 121-127 (2009).
76. Sugiyama E, Kaniwa N, Kim SR et al.: Pharmacokinetics of gemcitabine in Japanese cancer patients: the impact of a cytidine deaminase polymorphism. J. Clin. Oncol. 25(1), 32-42 (2007).
77. Tibaldi C, Giovannetti E, Vasile E et al.: Correlation of CDA, ERCC1, and XPD polymorphisms with response and survival in gemcitabine/cisplatin-treated advanced non-small cell lung cancer patients. Clin. Cancer Res. 14(6), 1797 - 1803 (2008).
78. Wong A, Soo RA, Yong WP, Innocenti F: Clinical pharmacology and pharmacogenetics of gemcitabine. Drug Metab. Rev. 41(2), 77-88 (2009).
79. Azzato EM, Pharoah PD, Harrington P et al.: A genome-wide association study of prognosis in breast cancer. Cancer Epidemiol. Biomarkers Prev. 19(4), 1140-1143 (2010).
80. Daly AK: Genome-wide association studies in pharmacogenomics. Nat. Rev. Genet. 11(4), 241-246 (2010).
81. Barrett JC, Hansoul S, Nicolae DL et al.: Genome-wide association defines more than 30 distinct susceptibility loci for Crohn's disease. Nat. Genet. 40(8), 955-962 (2008).
82. Zeggini E, Scott LJ, Saxena R et al.: Meta-analysis of genome-wide association data and large-scale replication identifies additional susceptibility loci for Type 2 diabetes. Nat. Genet. 40(5), 638-645 (2008).
83. Kim EJ, Jeong P, Quan C et al.: Genotypes of TNF-a, VEGF, hOGG1, GSTM1, and GSTT1: useful determinants for clinical outcome of bladder cancer. Urology 65(1), 70-75 (2005).
84. Mittal RD, Singh R, Manchanda PK et al.: XRCC1 codon 399 mutant allele: a risk factor for recurrence of urothelial bladder carcinoma in patients on BCG immunotherapy. Cancer Biol. Ther. 7(5), 645-650 (2008).
85. Gangwar R, Mandhani A, Mittal RD: XPC gene variants: a risk factor for recurrence of urothelial bladder carcinoma in patients on BCG immunotherapy. J. Cancer Res. Clin. Oncol. 136(5), 779-786 (2010).
86. Horikawa Y, Nadaoka J, Saito M et al.: Clinical implications of the MDM2 SNP309 and p53 Arg72Pro polymorphisms in transitional cell carcinoma of the bladder. Oncol. Rep. 20(1), 49-55 (2008).
87. Zhao H, Liang D, Grossman HB, Wu X: Glutathione peroxidase 1 gene polymorphism and risk of recurrence in patients with superficial bladder cancer. Urology 66(4), 769-774 (2005).
88. Lin J, Dinney CP, Grossman HB et al.: E-cadherin promoter polymorphism (C-160A) and risk of recurrence in patients with superficial bladder cancer. Clin. Genet. 70(3), 240-245 (2006).
89. Nadaoka J, Horikawa Y, Saito M et al.: Prognostic significance of HIF-1 a polymorphisms in transitional cell carcinoma of the bladder. Int. J. Cancer 122(6), 1297-1302 (2008).
90. Sakano S, Berggren P, Kumar R et al.: Clinical course of bladder neoplasms and single nucleotide polymorphisms in the CDKN2A gene. Int. J. Cancer 104(1), 98-103 (2003).
91. Riemann K, Struwe H, Eisenhardt A, Obermaier B, Schmid KW, Siffert W: Characterization of intron-1 haplotypes of the G protein b 4 subunit gene-association with survival and progression in patients with urothelial bladder carcinoma. Pharmacogenet. Genomics 18(11), 999-1008 (2008).
92. Mason RA, Morlock EV, Karagas MR et al.: EGFR pathway polymorphisms and bladder cancer susceptibility and prognosis. Carcinogenesis 30(7), 1155-1160 (2009).
93. Basturk B, Yavascaoglu I, Oral B, Goral G, Oktay B: Cytokine gene polymorphisms can alter the effect of Bacillus Calmette-Guerin (BCG) immunotherapy. Cytokine 35(1-2), 1-5 (2006).
94. Ahirwar DK, Agrahari A, Mandhani A, Mittal RD: Cytokine gene polymorphisms are associated with risk of urinary bladder cancer and recurrence after BCG immunotherapy. Biomarkers 14(4), 213-218 (2009).
95. Ahirwar DK, Mandhani A, Dharaskar A, Kesarwani P, Mittal RD: Association of tumour necrosis factor-a gene (T-1031C, C-863A, and C-857T) polymorphisms with bladder cancer susceptibility and outcome after bacille Calmette-Guerin immunotherapy. BJU Int. 104(6), 867-873 (2009).
96. Gangwar R, Ahirwar D, Mandhani A, Mittal RD: Do DNA repair genes OGG1, XRCC3 and XRCC7 have an impact on susceptibility to bladder cancer in the North Indian population? Mutat. Res. 680(1-2), 56-63 (2009).
97. Gangawar R, Ahirwar D, Mandhani A, Mittal RD: Impact of nucleotide excision repair ERCC2 and base excision repair APEX1 genes polymorphism and its association with recurrence after adjuvant BCG immunotherapy in bladder cancer patients of North India. Med. Oncol. 27(2), 159-166 (2010).
98. Gangwar R, Mandhani A, Mittal RD: Caspase 9 and caspase 8 gene polymorphisms and susceptibility to bladder cancer in north Indian population. Ann. Surg. Oncol. 16(7), 2028-2034 (2009).
99. Gangwar R, Mittal RD: Association of selected variants in genes involved in cell cycle and apoptosis with bladder cancer risk in north Indian population. DNA Cell Biol. 29(7), 349-356 (2010).
100. Decobert M, Larue H, Bergeron A et al.: Polymorphisms of the human NRAMP1 gene are associated with response to bacillus Calmette-Guerin immunotherapy for superficial bladder cancer. J. Urol. 175(4), 1506-1511 (2006).